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The 1st GOLDEN HELIX Symposium on ‘Copy number
variation and genomic alterations in health and disease’
was recently held in Athens, Greece, where some 160
participants from 31 countries were updated on recent
developments in the field of molecular cytogenetics, copy
number variation and the direction in which the
technology of array-based comparative genomic
hybridization (array-CGH) is evolving. The meeting was
supported by ten corporate entities, five of which
presented their technologies for array-CGH and/or
software tools for downstream analysis as company
lectures embedded in the scientific program. Here, we
report some highlights of this meeting from a genomic
perspective.
G GO OL LD DE EN N   H HE EL LI IX X   S Sy ym mp po os si ia a: :   t th he e   c co on nc ce ep pt t
The GOLDEN HELIX Symposia (http://www.
goldenhelixsymposia.org) are 2-3 day scientific meetings
aiming to advance biomedical and life sciences by bringing
together scientists within and across disciplines in the fields
of human genomics and personalized medicine. This
symposium series is named after the house of Francis Crick
(‘The Golden Helix’; 19/20 Portugal Place, Cambridge, UK)
to emphasize their focus on human genomics and
personalized medicine.
Conference venues are usually major cities or summer
retreats in the Southern Mediterranean or Middle East
regions. The symposia aim to maximize information
exchange and promote collaborative relationships between
regional research institutes and research centers of
excellence in the United States and Europe. Such
information exchange and collaboration ties are
strengthened by interactions between participants and
lecturers, the latter being internationally renowned
scientists, recognized leaders in their field. Selected
minireviews from the topics discussed in the symposia will
be published in special issues of Human Genomics and
Proteomics (http://www.sage-hindawi.com/journals/hgp).
A Ar rr ra ay y- -C CG GH H   t te ec ch hn no ol lo og gy y
Molecular cytogenetics aims to bridge the gap between
classical cytogenetics and modern molecular biology. In
general, this involves the use of a series of techniques
referred to as fluorescence in situ hybridization (FISH),
either directly on metaphase chromosomes or interphase
nuclei or indirectly using microarray-based comparative
genomic hybridization (array-CGH) analysis to assess the
entire genome for imbalanced chromosomal material.
Michael Speicher (Medical University of Graz, Austria)
provided a succinct overview of molecular cytogenetics.Increases in resolution are achieved by advances that involve
both the target and the probe, and microarray technologies
provide a description of chromosome structure at a resolution
that exceeds that of microscopic analysis. Array-CGH tech-
nology is an invaluable tool in oncology. Bauke Ylstra (Vrije
Universiteit Medical Center, Amsterdam, the Netherlands)
reported several applications of array-CGH in clinical
oncology for tumor identification and stratification. Like
Speicher, he stressed that integration of chromosomal copy
number variation (CNV) with gene expression will probably
identify new therapeutic targets that could not be identified
by analysis of independent platforms alone.
Diagnostic genome profiling can also be performed using
single nucleotide polymorphism (SNP) arrays. Joris Veltman
(Radboud University Nijmegen Medical Centre, Nijmegen,
the Netherlands) described the advantages of SNP arrays
over bacterial artificial chromosome (BAC) arrays for genome
profiling. In particular, with SNP arrays, intensity correlates
with genomic copy number, one-color hybridization is
performed and information on both genotype and copy
number variation is provided. A SNP array platform was
validated for the detection of submicroscopic deletions and
duplications in patients with unexplained mental retar-
dation, revealing rare de novo CNVs as explaining a signifi-
cant proportion of mental retardation. Joris Veltman stressed,
however, that CNV detection on commercial arrays is not yet
perfect, and it is important to improve software tools and
reference  samples and to increase sensitivity. Philippos
Patsalis (Cyprus Institute of Neurology and Genetics, Nicosia,
Cyprus) reported results from a custom-made X-chromosome-
specific array for targeted locus copy number assessment
and its application in understanding and characterizing the
biological causes of X-linked mental retardation and its
underlying mechanisms of X-chromosome disorders.
C Ch hr ro om mo os so om ma al l   d di is so or rd de er rs s   a an nd d   c co op py y   n nu um mb be er r   v va ar ri ia at ti io on n
As previously mentioned, CNVs are often implicated as a
cause of mental retardation and psychiatric disorders. Pawel
Stankiewicz (Baylor College of Medicine, Houston, USA)
reported the Baylor experience from a study of a large
number of mentally retarded patients who were screened
using molecular cytogenetic approaches. In particular, the
study showed that large recurrent microdeletions (for
example, on 1q21.1) and rare chromosomal deletions and
duplications are associated with schizophrenia, that genomic
alterations are also the cause of various cognitive disorders,
behavioral traits and autism, and that CNV duplication can
confer milder phenotypes than CNV deletion. Similarly,
Shane McCarthy (Cold Spring Harbor Laboratory, Cold
Spring Harbor, USA) described his research showing that,
on the basis of their collective frequency in cases and
controls, rare structural variants, both inherited and de novo
CNVs, are associated with schizophrenia, and that frequent
recurrent CNVs (e.g. on 1q21 and 15q13) are associated with
schizophrenia in large cohorts. He also stressed that similar
CNV risk factors may be shared between clinically distinct
disorders (e.g. schizophrenia and autism spectrum disorders).
Similar data were also presented by Corrado Romano (Oasi
Institute for Research on Mental Retardation and Brain
Aging, Troina, Italy), who reported the application of array-
CGH in determining the underlying genetic cause of mental
retardation and epilepsy.
Many visible chromosomal rearrangements occur de novo.
Orsetta Zuffardi (University of Pavia, Italy) described the use
of array-CGH to size unbalanced translocations and to reveal
the mechanisms that lead to these rearrangements. Copy
number alterations also occur frequently in human malig-
nancies, and Sakari Knuutila (Haartman Institute and Uni-
versity of Helsinki, Finland) reported numerous examples of
array-CGH revealing changes in the genomes of cancer
patients, including cryptic gene copy number alterations in
karyotypically normal cancers, uniparental disomy, dele-
tions in presumed ‘balanced translocations’, duplication of
fusion genes or detection of novel fusion genes, and episo-
mal gene amplification.
CNVs are also the cause of numerous novel syndromes, with
phenotypes varying from neoplasias and malformations to
growth and mental retardation, and Bert de Vries (Radboud
University Nijmegen Medical Centre) highlighted the use of
array-CGH in the identification of these syndromes. Finally,
gene dosage alterations can be often linked to disease
phenotypes. Lisenka Vissers (Radboud University Nijmegen
Medical Centre) highlighted two characteristic examples of
disease-causing gene identification through deletion map-
ping strategies, for CHARGE syndrome (coloboma, heart
malformation, atresia of choanae, retardation of growth and
development, genital hypoplasia, ear abnormality including
deafness) and 9q34 microdeletion syndrome.
P Po op pu ul la at ti io on n   g ge en no om mi ic cs s
CNV in DNA sequences probably has functional significance,
but this has yet to be ascertained. Previous studies showed
that approximately 12% of the human genome contains many
CNV regions, including genes, disease loci, segmental duplica-
tions and other functional elements. These studies also
revealed marked variation in copy number changes among
populations and delineated linkage disequilibrium patterns for
many CNVs. Richard Redon (Wellcome Trust Sanger Institute,
Hinxton, UK) outlined his research showing that several CNVs
are predisposing factors for several disorders, such as CNV in
the FCGR3 gene (encoding a low affinity IgG Fc receptor) that
predisposes to glomerulonephritis, and low human β-defensin
2 gene copy number that predisposes to Crohn’s disease. He
summarized ongoing projects to understand the impact of
CNVs on genes, characterize mutation mechanisms using
sequence content at CNV breakpoints, genotype CNVs for all
HapMap samples in order to characterize their population
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CNVs discovered in recent studies.
In some cases, CNVs have been shown to correlate with
subtle phenotypes in healthy individuals. Joris Veltman
(Radboud University Nijmegen Medical Centre) outlined
preliminary results from an ongoing collaborative project in
the Netherlands (the Brain Imaging Genetics project, BIG)
to delineate the genetics of brain function and activity using
brain endophenotypes, intermediate phenotypes that are
heritable and genetically less complex, with the future goal
of performing functional tests for significantly associated
genes and loci and investigating possible links to brain
disorders. Inherited, apparently benign CNVs can in some
cases cause disease, depending on copy number, inheritance
pattern or genetic and environmental background. Joris
Vermeesch (Katholiek Universiteit Leuven, Belgium)
described these so-called Mendelian CNVs, which cause
autosomal recessive, autosomal dominant, X-linked and
imprinted disorders. He provided examples, including
autosomal dominant inherited microtia, which results from
a 750 kilobase (kb) amplification on chromosome 4p, dupli-
cations in the X-linked genes MECP2 and  ATR-X, which
result in various forms of severe mental retardation, and
other examples of CNVs with variable expressivity and pene-
trance. He commented that the pace of Mendelian CNV
discovery is currently in an exponential phase.
Genetic variation influences gene expression, and this varia-
tion in gene expression can be efficiently mapped to specific
genomic regions. Moreover, variant gene expression is
heritable and differs between populations. Emmanouil
Dermitzakis (Wellcome Trust Sanger Institute) presented
preliminary data from expression quantitative trait locus
(QTL) analysis in eight human populations and three cell
types. He concluded that cis-acting genetic variation (both
SNPs and CNVs) influences gene expression and that
differences between cell types are due to both alternative use
of regulatory elements and differential levels of expression.
This session was closed by the keynote lecture ‘The renais-
sance of aneuploidy’, delivered by Stylianos Antonarakis
(University of Geneva School of Medicine, Switzerland), who
commented on the past, present and future of cytogenetics
and the impact of molecular cytogenetics in modern medical
practice and presented some key examples from significant
regulatory interactions in chromosome 21, using the 4C
(chromosome conformation capture on chip) technology.
P Pr re en na at ta al l   d di ia ag gn no os si is s
Congenital malformations are a major cause of morbidity
and mortality in infants. Chromosomal imbalances account
for approximately 10-15% of the cases, but in up to half the
patients the underlying genetic etiology of these malforma-
tions remains unknown. Array-CGH technology could,
therefore, facilitate detection of genomic imbalances in these
patients, and it could in the future be implemented for
routine prenatal diagnosis. Cédric le Caignec (University
Hospital, Nantes, France) presented results from a recent
study to estimate the feasibility and the rate of detection of
chromosomal abnormalities in fetuses with multiple
malformations, a first step before the implementation of
array-CGH in prenatal diagnosis. He concluded that array-
CGH is feasible from amniotic fluid or chorionic villus
samples and recommended a targeted array-CGH platform
to be designed for prenatal diagnosis; this could be used for
genome-wide screens for interstitial microdeletions and
known genetic syndromes, including in subtelomeric and
pericentromeric regions.
Comprehensive genome analysis of single cells is relevant
not only for cancer genetics, to monitor small levels of
residual disease after treatment and to assess heterogeneity
within a primary tumor, but also for clinical diagnostics,
breakpoint mapping, determination of mosaicism and
forensic applications. In addition, genome analysis at the
single cell level is important for non-invasive prenatal
diagnosis, for example, analysis of fetal cells (for example, in
maternal blood) and prenatal genetic screening (polar body
analysis). Jochen Geigl (Medical University of Graz) outlined a
representative whole-genome amplification protocol, coupled
to a high resolution array-CGH method that is technically
possible for single cells with the detection limit improved
from 6-8 megabases (Mb) to less than 3 Mb (and even
500 kb for 5-10 cells). He also showed that the haploid
genome from a polar body is suitable for array-CGH analysis
for the identification of aneuploidy patterns and mode of
chromosome segregation and for the detection of segmental
aneuploidies as small as 10 Mb. Geigl reported an array
painting method for rapid identification of disease-causing
genes in cases with structural rearrangements. Molecular
cytogenetic analysis is also feasible for ancient DNA samples
isolated from extinct species (such as the woolly mammoth),
Egyptian mummies, amber inclusions and coprolites. Holger
Tönnies (University Hospital Schleswig-Holstein, Kiel,
Germany) showed that conventional CGH analysis can be
used for DNA isolated from ancient tissues to detect
chromosomal aberrations, although the establishment of a
reliable (unbiased) ancient DNA amplification protocol and
a downstream array-CGH analysis for these purposes
remains challenging.
Q Qu ua al li it ty y   c co on nt tr ro ol l
With so many commercial and customized array-CGH
platforms currently available, there is a need for a consensus
on a uniform and evidence-based platform for constitutional
diagnostic oligonucleotide array-CGH, an array-CGH platform
allowing researchers to survey the entire human genome for
chromosomal abnormalities. John Crolla (National Genetics
Reference Laboratory Wessex, Salisbury, UK) outlined the
aims of an international consortium recently formed to design
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to interpret array-CGH results. The consortium works
towards reaching an agreement to create an evidence-based
process for clinical array design, to set uniform guidelines
for interpretation and reporting of array-CGH results, and to
develop a centralized data repository for array abnormalities
and benign variants. It has been agreed to cover all currently
known microdeletion/microduplication and syndromic
regions, of which there about 500 known so far, in order to
achieve maximum backbone resolution with the probes
available (which are about 30 kb long). Future challenges
would be to define the minimum resolution for a diagnostic
array-CGH and to host a ‘cytogenetic’ database of genomic
variants in the DECIPHER database (database of
chromosomal imbalance and phenotype in humans using
ensembl resources, s) and/or other genome browsers [such
as those at the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/) and the
University of California at Santa Cruz (http://
genome.ucsc.edu/)] for worldwide access.
Jacqueline Schoumans (Karolinska Institute, Stockholm,
Sweden) reported a stepwise approach for validating the
implementation of array-CGH platforms in the diagnostic
setting. The ideal array-CGH platform should: (i) be cost-
effective, widely used and with a probe design (share benign
CNVs) for optimum resolution (at least down to 300 kb) to
reliably detect CNVs; (ii) be commercially available; (iii)
have a less laborious workflow than current platforms and
include user-friendly software packages and certification of
analysis; and (iv) make it possible to design custom arrays.
Finally, Marcella Zollino (Università Cattolica del Sacro
Cuore, Rome, Italy) concluded the meeting by presenting a
checklist with criteria for selecting patients for array-CGH
analysis and for validating subsequent results.
C Co on nc cl lu us si io on ns s
Overall, the 1st GOLDEN HELIX Symposium highlighted
several main themes: the importance of CNV and genomic
alterations in health and disease; the emerging array-CGH
technology as a powerful and accurate tool for revealing
existing and novel genomic alterations with high resolution
in chromosomal and other disorders, such as schizophrenia,
mental and growth retardation and malignancies; the
occurrence of CNVs in healthy individuals and their relation
to gene expression differences; the application of array-CGH
in prenatal diagnosis and in the analysis of single cells; and
the need for a uniform and evidence-based constitutional
array-CGH platform. Gathering scientists from all these
different disciplines allowed for cross-fertilization of ideas,
thereby setting the horizon for new cutting edge research to
be discussed at the next GOLDEN HELIX Symposium on
CNVs, scheduled for 2010 in the Athenian Riviera.
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